Milestone Pharmaceuticals, Inc. is a late-stage biopharmaceutical company developing its Phase III product candidate, etripamil, for the treatment of cardiovascular indications.
In order to optimize our website for you and to be able to continuously improve it, we use cookies. By continuing to use the website, you agree to the use of cookies. Further information on cookies can be found in our Privacy Policy.